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Coronary Revascularization
and Stroke*
Jesse Weinberger, MD,† Craig Smith, MD‡
New York, New York
The SYNTAX (SYNergy Between PCI With TAXUS and
Cardiac Surgery) trial (1) was designed to determine
whether treatment of complex coronary artery disease with
percutaneous coronary intervention (PCI) with a drug-
eluting stent was noninferior to treatment with coronary
bypass surgery (CABG). The overall outcome analysis
demonstrated that the rate of major adverse cardiac or
cerebrovascular events was significantly higher in the PCI
group (17.8%) compared with the CABG group (12.4%)
(p  0.002). However, the rate of stroke was significantly
See page 344
higher in the CABG group, reported as (2.2%) compared
with the PCI group (0.6%) (p  0.003) in the original
YNTAX paper. The study by Mack et al. (2) in this issue
f JACC: Cardiovascular Interventions, focused specifically
n stroke, reports a stroke difference of 1% (CABG) versus
.2% (PCI) at 0 to 30 days by intent-to-treat (p  0.037),
nd 3 of the 9 strokes in the CABG group occurred
re-operatively, so a statistically meaningful difference in an
s-treated analysis is doubtful. Nonetheless, an increased
ate of stroke with CABG has been observed in the majority
f other comparative studies (3), acknowledging, as with
YNTAX, that none were powered to assess an event as
nfrequent as stroke. The increase in the rate of early,
erioperative stroke does not detract from the overall
uperiority of CABG for prevention of the combined
ndpoints of these studies, but any increase in stroke risk
auses considerable concern because of the impact of stroke
n quality of life. The current paper analyzes the possible
auses of the increased incidence of stroke in patients
reated with CABG in attempt to find methods for preven-
ion of stroke in the future (2).
*Editorials published in JACC: Cardiovascular Interventions reflect the views of the
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o disclose.The overall incidence of stroke after 4 years of follow-up was
3 in the CABG arm with 2 patients sustaining 2 strokes, and
as 20 in the PCI arm with 1 patient sustaining 2 strokes (p
.06). As noted in the previous text, 9 of the 33 strokes
ccurred within 30 days of the procedure in the CABG arm
ompared with 2 of 20 in the PCI arm. Stroke after cardiac
urgery has traditionally been assessed from 0 to 30 days, on the
ssumption that early events, whether attributed to intraoper-
tive technique, patient factors, or atrial fibrillation (4), have
ome likely causal relationship to the procedure. In this paper
2), the subsequent rate of stroke in the 2 groups after 30 days,
hich reflects the natural history of stroke in these patients
ith severe vascular disease, was similar: 24 of 33 in the CABG
rm and 18 of 20 in the PCI arm.
The fact that 3 of the strokes in the CABG arm occurred
rior to surgery suggests that discontinuation of antithrom-
otic therapy may play a role in the increased incidence of
troke, particularly in patients on anticoagulation for stroke
revention from atrial fibrillation. It is not documented
hether these 3 strokes occurred in patients with atrial fibril-
ation. However, patients treated with PCI are maintained on
ual antiplatelet therapy with aspirin and thienopyridines
uring the procedure. Patients treated with CABG are either
ot maintained on antithrombotic therapy or are treated with
spirin alone during the perioperative period because of the risk
f bleeding (4). This may lead to a greater susceptibility to
erebral embolic events before, during, and after the procedure.
he authors considered this explanation for the 3 preoperative
trokes, and concluded that only 1 of the 3 occurred at a time
1 day pre-operatively) when discontinuation of antithrom-
otic agents was a likely factor. Dual antiplatelet therapy
ould not play a role in the long-term outcome for stroke in
hese patients. There was no difference in stroke incidence
etween the PCI arm and the CABG arm in long-term
ollow-up after the perioperative period, and combined
herapy with aspirin and clopidogrel has not been shown to
e more effective than either clopidogrel or aspirin alone in
he prevention of recurrent stroke with a significant and
nacceptable increase of intracranial hemorrhage (5,6).
Other etiologies that have been implicated for stroke
uring CABG include coexisting significant carotid artery
tenosis, embolic events from plaque due to manipulation of
he aorta, and systemic hypotension producing watershed
nfarction (4). In the SYNTAX trial, the prevalence of
ignificant carotid stenosis was equal in the PCI (8.1%) and
ABG (8.4%) arms (1) and did not influence the frequency
f stroke, although the number of events was too low to be
efinitive (2). Carotid surgery before or during CABG has
lso not been shown to be beneficial in reducing the rate of
troke and may increase the number of adverse events (4).
ff-pump coronary bypass surgery has the theoretical ad-
antage of avoiding emboli from aortic cannulation and
ther pump-related factors, but there was no influence of
ff-pump surgery on stroke incidence in the current study
r
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356(3) or as reported in a recent review (4). The common risk
factors for stroke including increased age, hypertension,
poor left ventricular function (left ventricular ejection frac-
tion) and angina were associated with an increased risk of
stroke in the current study, but the increased risk was
equivalent for both treatment arms. New onset of atrial
fibrillation was actually a greater predictor of stroke in the PCI
arm than the CABG arm. Diabetes was not associated with an
increase in the incidence of stroke. The recently completed
FREEDOM (Comparison of Two Treatments for Multives-
sel Coronary Artery Disease in Individuals With Diabetes)
trial comparing drug-eluting stents to coronary bypass surgery
in diabetic patients with multivessel coronary artery occlusive
disease demonstrated a similar significant increase in stroke
with coronary bypass surgery compared with percutaneous
stenting. An analysis of the etiology of stroke in these patients
has not yet been performed (7).
The SYNTAX study was not specifically designed to
determine the etiology of stroke in patients treated with
CABG or PCI. It is imperative to establish the causes of the
increased risk of stroke during CABG and develop strategies to
prevent these strokes, because the overall outcome for preven-
tion of cardiovascular disease is so significant. A prospective
study may be warranted to analyze risk factors and define
stroke subtype with methodology employed in trials of acute
stroke management and prevention of recurrent stroke (8,9).
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